Arcellx (ACLX) Liabilities and Shareholders Equity (2021 - 2025)
Arcellx's (ACLX) quarterly Liabilities and Shareholders Equity came in at $604.0 million in Q4 2025, down 15.09% year-on-year from $711.3 million in Q4 2024, and down 7.92% quarter-over-quarter from $655.9 million in Q3 2025.
Arcellx (ACLX) Liabilities and Shareholders Equity (2021 - 2025) Analysis & Trends
Arcellx's Liabilities and Shareholders Equity history runs 5 years deep, the most recent figure standing at $604.0 million for Q4 2025.
- On a quarterly basis, Liabilities and Shareholders Equity fell 15.09% year-over-year to $604.0 million in Q4 2025; TTM through Dec 2025 was $2.5 billion, a 15.49% decrease from a year earlier, with the FY2025 full-year figure at $604.0 million, down 15.09% from the prior year.
- Liabilities and Shareholders Equity declined to $604.0 million in Q4 2025 per ACLX's latest filing, from $655.9 million in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $825.1 million in Q4 2023 and bottomed at $128.8 million in Q4 2021.
- The 5-year median for Liabilities and Shareholders Equity is $622.9 million (2023), against an average of $565.0 million.
- Across the five-year window, Liabilities and Shareholders Equity jumped 162.93% in 2023 and declined 16.88% in 2025, its largest moves.
- Year by year, Liabilities and Shareholders Equity stood at $128.8 million in 2021, then soared by 143.68% to $313.8 million in 2022, then soared by 162.93% to $825.1 million in 2023, then fell by 13.79% to $711.3 million in 2024, then slipped by 15.09% to $604.0 million in 2025.
- Per Business Quant, the three latest ACLX Liabilities and Shareholders Equity figures stand at $604.0 million (Q4 2025), $655.9 million (Q3 2025), and $619.1 million (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 311.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 78.88 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 8.55 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 39.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 26.48 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 40.87 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 811.27 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 10.03 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.25 Bn |
| 10 | Arcellx | 6.48 Bn | 6.48 Bn | - | 603.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 603.99 Mn |
| Sep 30, 2025 | 655.92 Mn |
| Jun 30, 2025 | 619.09 Mn |
| Mar 31, 2025 | 648.08 Mn |
| Dec 31, 2024 | 711.33 Mn |
| Sep 30, 2024 | 764.91 Mn |
| Jun 30, 2024 | 734.31 Mn |
| Mar 31, 2024 | 779.70 Mn |
| Dec 31, 2023 | 825.13 Mn |
| Sep 30, 2023 | 614.22 Mn |
| Jun 30, 2023 | 623.53 Mn |
| Mar 31, 2023 | 622.94 Mn |
| Dec 31, 2022 | 313.82 Mn |
| Sep 30, 2022 | 337.33 Mn |
| Jun 30, 2022 | 374.66 Mn |
| Mar 31, 2022 | 246.98 Mn |
| Dec 31, 2021 | 128.78 Mn |